EU approves Enhertu-pertuzumab combo for first-line HER2-positive breast cancer

{
  "signal_id": "0abaf434-2fb6-8912-bec5-4aa570725a39",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-01T14:46:15+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.thepharmaletter.com/biotech-news/eu-approves-enhertu-pertuzumab-combo-for-first-line-her2-positive-breast-cancer",
    "title": "EU approves Enhertu-pertuzumab combo for first-line HER2-positive breast cancer - thepharmaletter.com",
    "excerpt": "The European Commission (EC) has approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, Anglo-Swedish firm AstraZeneca (LSE: AZN) and its Japanese partner Daiichi Sankyo (TYO: 4568) announced. This approval, based on a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, marks the first new regimen in this first-line setting in more than a decade.",
    "product": "Enhertu",
    "summary": "AstraZeneca and its partner Daiichi Sankyo received approval from the European Commission for their drug Enhertu, in combination with pertuzumab, as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.",
    "location": "Europe",
    "planning": false,
    "image_url": "https://cdn.thepharmaletter.com/convert/files/2026/01/e0efb010-eaff-11f0-a6a3-f76d6da058d6-AstraZeneca%20Large.jpg/r%5Bwidth%5D=1280/e0efb010-eaff-11f0-a6a3-f76d6da058d6-AstraZeneca%20Large.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "Enhertu",
      "full_text": "Enhertu (trastuzumab deruxtecan)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-01T14:46:15Z",
    "location_data": [
      {
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The European Commission (EC) has approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, Anglo-Swedish firm AstraZeneca (LSE: AZN) and its Japanese partner Daiichi Sankyo (TYO: 4568) announced.",
    "related_company_name": "Daiichi Sankyo",
    "related_company_domain": "daiichisankyo.com"
  }
}

curl https://signals.autobound.ai/v1/signals/0abaf434-2fb6-8912-bec5-4aa570725a39 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'